Comparative test of the effectiveness of T-1220 (Piperacillin) and ampicillin on respiratory tract infection by double blind method

Keiichi Nakagawa, Junzaburo Kabe, Kentaro Watanabe, Norio Kihara, Masaru Koyama, Yasumichi Kato, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Tatsunori Shimizu, Fumio Nagahama, Takehito Nakabayashi, Takeshi Kimura, Rinji Kawana, Tsukasa Yoshida, Yasuo Usui, Hitoshi Takishima, Sumio Arai, Kiyoshi Konno, Kotaro OizumiAkira Watanabe, Masataka Katsu, Toshihiro Fujii, Mitsuharu Narita, Akio Kobayashi, Yoshiko Maruyama, Keimei Mashimo, Kazufuto Fukaya, Otohiko Kunii, Yasushi Ueda, Atsushi Saito, Fumio Matsumoto, Kihachiro Shimizu, Kaoru Shimada, Hiomi Homma, Keiko Inatomi, Ikko Watanabe, Hiroichi Tanimoto, Osamu Kitamoto, Hiroyuki Kobayashi, Ippei Fujimori, Yasuo Matsuoka, Kokichi Fukushima, Akira Ito, Ryuichiro Yamazaki, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Fusanosuke Yamasaku, Yasutoshi Suzuki, Masanaga Takato, Fumihide Iwata, Kohei Kameyama, Kaoru Ohyama, Michiko Kaneki, Teruhiko Hibi, Yoshinori Nakamura, Takeshi Miyazawa, Toshiyuki Yamamoto, Sakae Kan, Saburo Kitaura, Yukio Goto, Masaru Onuma, Katsutaka Torikai, Nobuo Maekawa, Michiyasu Nakanishi, Kenji Bando, Hideki Nishiyama, Eiichi Yamada, Shigeyoshi Kado, Tatsuo Ishibashi, Jun Nakai, Takekuni Iwata, Kenzo Shiota, Fumio Miki, Tomokazu Asai, Hiroshi Ohkubo, Yuruko Okamoto, Fumihiko Uba, Yoshihiro Ueda, Keigo Maehara, Takehiro Tsujimoto, Sakimori Yamaguchi, Takayasu Tsuda, Natsuo Nishizawa, Shoichi Kawamura, Rinzo Soejima, Yoshihiko Tano, Takehiko Kobayashi, Naomi Kimura, Osamu Kurimura, Hideo Sasaki, Kazue Tamaki, Koji Sinagawa, Eiro Tsubura, Michiaki Kawano, Kusuji Kawahara, Midori Takasugi, Akira Murakami, Yuichi Murakoshi, Unpei Shigemi, Toshiyuki Yanase, Yoshiro Sawae, Nobuyoshi Sato, Shiro Kameda, Koutaro Sugiyama, Tsuneo Ishibashi, Masahiro Takamoto, Kohei Hara, Masaru Nasu, Masao Nakatomi, Atsushi Saito, Toshiyuki Oe, Nobuhiro Horiuchi, Hirohide Fukuda, Kinichi Izumikawa, Tsuneo Tsutsumi, Rokushi Oka, Toshio Yonashiro, Keizo Matsumoto, Makoto Imaoka, Yoshio Uzuka, Hiroshi Suzuki, Masatoshi Ide, Tamiharu Mori, Hisao Kimura, Haruhiko Tokuomi, Kiyoshi Shima, Yasutsugu Fukuda, Kazuhiro Hamada, Katsumasa Tokunaga, Takayuki Aoki, Ryuii Kaku, Mineharu Sugimoto, Hideo Koga, Hiroshi Yamaguchi, Kazuo Ishizaka, Mamoru Akatsuka, Akio Ohba, Masayuki Ando

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    The clinical effectiveness and safety of T-1220 (Piperacillin) and ABPC (Ampicillin) were compared in this randomized, double-blind multi-clinical study of 297 patients with respiratory tract infections. Patients were assigned to treatment with either 4g/day of T-1220 or 2g/day of ABPC by drip infusion for 7 to 14 days. The results obtained were as follows: 1. Two hundreds and twenty-eight patients were selected for evaluation by committee members. Among these patients, 117 were treated with T-1220 and 111 were treated with ABPC. Each number of patients administered either T-1220 or ABPC was 35 and 33 in bacterial pneumonia, 28 and 22 in mycoplasmal pneumonia, 16 and 10 in primary atypical pneumonia (PAP), and 38 and 46 in chronic respiratory tract infections, respectively. 2. On the other hand, two hundreds and fifty-eight patients were selected, excepting that was remarkably against the rule, the number of cases adopted as able as possible by doctors in charge. Among these patients, 127 were treated with T-1220 and 131 were treated with ABPC. Each number of patients administered either T-1220 or ABPC was 65 and 50 in bacterial pneumonia, and 40 and 53 in chronic respiratory tract infections, respectively. 3. The overall clinical efficacy rate (excellent and good results) in all cases adopted by committee members was 65.8% in T-1220 group and 58.6% in ABPC group, respectively. In the cases of bacterial pneumonia the efficacy rate was 77.2% in T-1220 group and 60.6% in ABPC group. The effectiveness in T-1220 group was significantly to that in ABPC group. In the cases of chronic respiratory tract infections the efficacy rate was 67.5% in T-1220 group and 47.2% in ABPC group. 4. The overall clinical efficacy rate in all cases adopted by doctors in charge was 71.7% in T-1220 group and 53.4% in ABPC group, respectively. The effectiveness in T-1220 group was significantly to that in ABPC group. In the cases of bacterial pneumonia the efficacy rate was 81.5% in T-1220 group and 64.0% in ABPC group. In the cases of chronic respiratory tract infections the efficacy rate was 67.5% in T-1220 group and 47.2% in ABPC group. The effectiveness in T-1220 group was significantly to that in ABPC group for both diseases. 5. T-1220 showed an excellent effect for improvement of symptoms and findings of chest roentgenogram, cough and volume of sputum in bacterial pneumonia, and dyspnea, chest pain, râles and cyanosis in chronic respiratory tract infections. The results obtained in T-1220 group was significantly to that in ABPC group. 6. No significant difference was observed in the frequency of side effect between both groups. 7. From the results obtained in all the patients, the utility of T-1220 was considered to be significantly to that of ABPC. In particular, the utility of T-1220 against bacterial pneumonia and chronic respiratory tract infections was judged to be superior to that of ABPC.

    Original languageEnglish
    Pages (from-to)123-166
    Number of pages44
    JournalChemotherapy
    Volume26
    Issue number2
    DOIs
    Publication statusPublished - 1978

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Comparative test of the effectiveness of T-1220 (Piperacillin) and ampicillin on respiratory tract infection by double blind method'. Together they form a unique fingerprint.

    Cite this